Life Sciences, deals, startups

Synageva Finishes $45M Round

Ryan McBride 10/20/09

Synageva BioPharma, a Waltham, MA-based developer of new and generic biotech drugs, said this morning that it has raised $12 million, on top of $33 million announced in May, to complete a $45 million round of financing. The round included previous investors as well as a new investor, New Leaf Venture Partners, of New York and Menlo Park, CA. Srini Akkaraju, a managing director at New Leaf, is joining the board of directors at Synageva in connection with his firm’s investment in the company.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.